EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Survey of Canadian Physician Use of Botulinum Toxin A (BoNT-A) for Paratonia: Real World Insights

Galit Kleiner iD, Farooq Ismail, Omar Khan, Christopher Pilieci, Linda Truong, Chris Boulias

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · 2025

DOI: 10.1017/cjn.2024.46 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2025. Verfasst von Galit Kleiner und 5 weiteren Autor:innen. Beteiligte Einrichtung: Austin Centre for Neurology and Behavioral Supports, Baycrest Health Sciences, Katz Interprofessional Research Program in Geriatric Dementia Care, Ro…. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Neuromuscular Agents, Muscle Hypertonia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Paratonia is a form of hypertonia characterized by an inability to relax muscles in the setting of cognitive impairment. Paratonia results in pain, refusal of care, and caregiver burden. We sent surveys to 67 Canadian physiatrists and neurologists regarding their experience treating paratonia with botulinum toxin A (BoNT-A). Twenty-seven survey respondents were included in the analysis. Thirteen percent of survey respondents treating paratonia with BoNT-A reported a significant clinically relevant improvement; 74% endorsed a moderately clinically relevant improvement; 13% endorsed a slight clinically relevant improvement. Ninety percent of survey respondents endorsed significant barriers in treating paratonia with BoNT-A.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type ANeuromuscular AgentsMuscle HypertoniaHumansCanadaSurveys and QuestionnairesPhysiciansFemaleMaleNeurologistsPractice Patterns, Physicians'Physiatrists

Stichwörter der Autor:innen

Canadabotulinumtoxin-Adementiaparatoniaphysiciansurvey

Substanzen

Botulinum Toxins, Type ANeuromuscular Agents

Autor:innen und Institutionen

  • Austin Centre for Neurology and Behavioral Supports, Baycrest Health Sciences, Katz Interprofessional Research Program in Geriatric Dementia Care, Rotman Research Institute, Toronto, ON, Canada.
  • Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • West Park Health Care Center, Toronto, ON, Canada.
  • Division of Physiatry, Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • Hotel Dieu Shaver Health and Rehabilitation Centre, St. Catherine's, ON, Canada.
  • Division of Physiatry, Dept of Medicine, McMaster University, St. Catherine's, ON, Canada.

ORCID-Profile: Galit Kleiner

Zitieren

APA

Kleiner, G., Ismail, F., Khan, O., Pilieci, C., Truong, L., & Boulias, C. (2025). Survey of Canadian Physician Use of Botulinum Toxin A (BoNT-A) for Paratonia: Real World Insights. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. https://doi.org/10.1017/cjn.2024.46

Vancouver

Kleiner G, Ismail F, Khan O, Pilieci C, Truong L, Boulias C. Survey of Canadian Physician Use of Botulinum Toxin A (BoNT-A) for Paratonia: Real World Insights. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 2025. doi:10.1017/cjn.2024.46

BibTeX
@article{Kleiner2025,
  author = {Kleiner, Galit and Ismail, Farooq and Khan, Omar and Pilieci, Christopher and Truong, Linda and Boulias, Chris},
  title = {Survey of Canadian Physician Use of Botulinum Toxin A (BoNT-A) for Paratonia: Real World Insights},
  journal = {Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques},
  year = {2025},
  doi = {10.1017/cjn.2024.46}
}
Kostenlos starten →